Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
| Autor: | Samuel Z. Goldhaber, Madan Jagasia, Javid Moslehi, Daryl Patton, Greg Piazza, Houston Wyatt, Robert Hall, Robert F. Cornell, Brian G. Engelhardt, Shelton L. Harrell |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty immunomodualtors Deep vein anticoagulation (AC) lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Methods cardiovascular diseases Multiple myeloma Lenalidomide business.industry Apixaban (Eliquis®) Pomalidomide medicine.disease equipment and supplies lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Thrombosis Pulmonary embolism Thalidomide 030104 developmental biology medicine.anatomical_structure myeloma Oncology venous thomboembolism 030220 oncology & carcinogenesis Apixaban business medicine.drug |
| Zdroj: | Frontiers in Oncology, Vol 9 (2019) Frontiers in Oncology |
| DOI: | 10.3389/fonc.2019.00045/full |
| Popis: | Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, have improved survival of patients with multiple myeloma (MM). However, these therapies are associated with an increased risk of venous thromboembolism (VTE). Apixaban has been approved for treatment of acute VTE and for risk reduction of recurrent VTE following initial therapy. In this phase IV single-arm study (NCT02958969), we aim to prospectively evaluate the safety and efficacy of apixaban for primary prevention of VTE in patients with MM. The primary efficacy objective of this trial is to determine the rate of symptomatic VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), over 6 months. The primary safety objective is to determine the rate of major bleeding in MM patients receiving apixaban prophylaxis. If proven safe and effective, apixaban will emerge as a promising option for oral VTE prophylaxis in MM patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|